Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 17, 2024
Daily News
January 17, 2024
- MHLW Publishes Report on Drug Marketing System towards PMD Law Amendment
January 17, 2024
- Resuming Production at Quake-Hit Plant Will Take Some Time: Santen
January 17, 2024
- Daiichi Sankyo to Discontinue Sales of Herceptin Biosimilar in November
January 17, 2024
- MHLW Issues Notification to Clarify Orphan Designation Criteria
January 17, 2024
- Taisho Set for Delisting as Early as April after Tender Offer Completed
January 17, 2024
- Taisho’s Nanozora Autoinjector Goes on Sale in Japan
January 17, 2024
- Amgen Files TED Drug Tepezza in Japan
January 17, 2024
- Novo Nordisk Begins Normal Shipments for Ozempic in Japan
January 17, 2024
- Introduction of Elective Care to Mark Watershed for Long-Listed Drug Makers
January 17, 2024
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…